These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 9076662)

  • 1. Simvastatin impairs mitogen-induced proliferation of malignant B-lymphocytes from humans--in vitro and in vivo studies.
    Vitols S; Angelin B; Juliusson G
    Lipids; 1997 Mar; 32(3):255-62. PubMed ID: 9076662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
    Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
    Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro.
    Kurakata S; Kada M; Shimada Y; Komai T; Nomoto K
    Immunopharmacology; 1996 Aug; 34(1):51-61. PubMed ID: 8880225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
    Naoumova RP; Marais AD; Mountney J; Firth JC; Rendell NB; Taylor GW; Thompson GR
    Atherosclerosis; 1996 Jan; 119(2):203-13. PubMed ID: 8808497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein.
    Sakai M; Kobori S; Matsumura T; Biwa T; Sato Y; Takemura T; Hakamata H; Horiuchi S; Shichiri M
    Atherosclerosis; 1997 Aug; 133(1):51-9. PubMed ID: 9258407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.
    Qin W; Infante J; Wang SR; Infante R
    Biochim Biophys Acta; 1992 Jul; 1127(1):57-66. PubMed ID: 1627634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens.
    Mosley ST; Kalinowski SS; Schafer BL; Tanaka RD
    J Lipid Res; 1989 Sep; 30(9):1411-20. PubMed ID: 2513368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors.
    Kleinveld HA; Demacker PN; De Haan AF; Stalenhoef AF
    Eur J Clin Invest; 1993 May; 23(5):289-95. PubMed ID: 8354335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypercholesterolaemia: simvastatin and pravastatin alter cholesterol metabolism by different mechanisms.
    Owens D; Collins P; Johnson A; Tighe O; Robinson K; Tomkin GH
    Biochim Biophys Acta; 1991 Apr; 1082(3):303-9. PubMed ID: 1903069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types.
    Nègre-Aminou P; van Vliet AK; van Erck M; van Thiel GC; van Leeuwen RE; Cohen LH
    Biochim Biophys Acta; 1997 Apr; 1345(3):259-68. PubMed ID: 9150246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors.
    Newman A; Clutterbuck RD; Powles RL; Catovsky D; Millar JL
    Leuk Lymphoma; 1997 Feb; 24(5-6):533-7. PubMed ID: 9086443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of simvastatin on plasma lipid and lipoprotein concentrations and low-density lipoprotein metabolism in the nephrotic syndrome.
    Warwick GL; Packard CJ; Murray L; Grierson D; Stewart JP; Shepherd J; Boulton-Jones JM
    Clin Sci (Lond); 1992 Jun; 82(6):701-8. PubMed ID: 1320552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of simvastatin (MK-733) on the regulation of cholesterol synthesis in Hep G2 cells.
    Nagata Y; Hidaka Y; Ishida F; Kamei T
    Biochem Pharmacol; 1990 Aug; 40(4):843-50. PubMed ID: 2167097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of cholesterol synthesis and hepatic 3-hydroxy-3-methylglutaryl--CoA reductase in rats by simvastatin and pravastatin.
    Del Puppo M; Rauli S; Galli Kienle M
    Lipids; 1995 Nov; 30(11):1057-61. PubMed ID: 8569435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity.
    Pazzucconi F; Dorigotti F; Gianfranceschi G; Campagnoli G; Sirtori M; Franceschini G; Sirtori CR
    Atherosclerosis; 1995 Oct; 117(2):189-98. PubMed ID: 8801864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormal regulation of the LDL-R and HMG CoA reductase genes in subjects with familial hypercholesterolemia with the "French Canadian mutation".
    Yu L; Qiu S; Genest J
    Atherosclerosis; 1996 Jul; 124(1):103-17. PubMed ID: 8800498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.
    Conde K; Pineda G; Newton RS; Fernandez ML
    Biochem Pharmacol; 1999 Oct; 58(7):1209-19. PubMed ID: 10484079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
    Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M
    Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.